Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vestn Oftalmol ; 132(2): 85-89, 2016.
Artigo em Russo | MEDLINE | ID: mdl-27347571

RESUMO

The article summarized the results of Russian and foreign research concerning biomechnical principles of eye functioning as an integral physiological system. Quite a number of studies have been published on corneal and scleral mechanics, which is also part of the said system. These studies fall largely into three groups: in vivo studies (involving living organism), in vitro studies (within an artificial environment), and mathematical modeling. In vivo techniques are often rather complicated and, therefore, most studies are based on in vitro procedures. Due to the growing number of intravitreal injections, they can be regarded as a stress test for studying fibrous tunic biomechanics in vivo. The results of such studies would contribute to a better understanding of the pathogenesis of various eye diseases and thus, a better clinical practice.


Assuntos
Córnea , Fenômenos Fisiológicos Oculares , Esclera , Fenômenos Biomecânicos , Córnea/fisiologia , Córnea/fisiopatologia , Humanos , Modelos Biológicos , Modelos Teóricos , Esclera/fisiologia , Esclera/fisiopatologia
2.
Vestn Oftalmol ; 131(3): 27-33, 2015.
Artigo em Russo | MEDLINE | ID: mdl-26310004

RESUMO

AIM: to evaluate the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration (AMD) and glaucoma. MATERIAL AND METHODS: The study enrolled 117 patients (117 eyes) with exudative AMD and concomitant non-operated primary open-angle glaucoma (POAG). All patients were divided into several groups depending on their intraocular pressure (IOP) and stage of POAG. Hypotensive therapy included carbonic anhydrase inhibitors, beta-adrenergic antagonists (beta blockers) and alpha(2)-adrenergic agonists (alpha-2 mimetics). Lucentis (ranibizumab) was intravitreally injected thrice at monthly intervals. All patients underwent a standard ophthalmic examination, fluorescent retinal angiography, and optical coherence tomography. IOP was measured before the first and after the last injection by means of Icare PRO reboud tonometer. RESULTS: There was no statistically significant difference between groups Ia, IIa, Ib, and IIb in terms of IOP elevation. Glaucoma IIc and IIIa patients showed just a moderate increase in IOP that did not require regimen adjustment. There was, however, a single IIIb case of persistent IOP elevation, in which one-step penetrating trabeculectomy with intravitreal ranibizumab injection was later performed. Resolution of macular edema was achieved in all patients. Visual acuity (VA) varied between the groups demonstrating a tendency toward improvement in glaucoma Ia patients (p = 0.062) and stabilization in glaucoma IIa (p = 0.61), Ib (p = 0.07), and IIb (p = 0.29) patients. In some cases of low vision at baseline and subretinal fibrosis, VA changes were of no clinical significance. CONCLUSIONS: Intravitreal ranibizumab therapy proved effective in exudative age-related macular degeneration with concomitant glaucoma. Timely treatment of both AMD (i.e. before the development of subretinal fibrosis) and glaucoma contributes to therapeutic success in these patients.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Glaucoma/tratamento farmacológico , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Degeneração Macular Exsudativa/tratamento farmacológico , Inibidores da Angiogênese/administração & dosagem , Bevacizumab , Angiofluoresceinografia , Fundo de Olho , Glaucoma/complicações , Glaucoma/fisiopatologia , Humanos , Pressão Intraocular , Injeções Intravítreas , Ranibizumab , Tomografia de Coerência Óptica , Acuidade Visual , Degeneração Macular Exsudativa/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA